

## DAFTAR PUSTAKA

1. Ma J, Cao S. The epidemiology of nasopharyngeal carcinoma. In: Lu JJ, Cooper JS, Lee AW, editors. *Nasopharyngeal cancer multidisciplinary management*. 1st ed. New York: Springer; 2010. 1-7.
2. Petersson F. Nasopharyngeal carcinoma: A review. *Semin Diagn Pathol*. 2015;32(1):54-73
3. Kimura Y, Suzuki D, Tokunaga T, Takabayashi T. Epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan during the period from 1996 to 2005. *Auris Nasus Larynx*. 2011;38(2):244-9.
4. Poh SS, Lee M, Chua K, Wee JTS. Carcinogenesis of nasopharyngeal carcinoma : an alternate hypothetical mechanism. *Chin J Cancer*. 2016;35:1-9.
5. Ferrari D, Codecà C, Bertuzzi C, et al. Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a western population. 2012;12:1-7.
6. Chen M, Yin L, Wu J, et al. Impact of Plasma Epstein-Barr Virus-DNA and Tumor Volume on Prognosis of Locally Advanced Nasopharyngeal Carcinoma. 2015;1-5.
7. Mahdavifar N, Ghoncheh M. Epidemiology and Inequality in the Incidence and Mortality of Nasopharynx Cancer in Asia. *Osong Public Heal Res Perspect*. 2016;7(6):360-72.
8. JKS W, CAV H. *Nasopharyngeal Carcinoma*. In *Scott-Brown's Otorhinolaryngology, Head and Neck Surgery*. 7th ed. (M G, MJ B, R C, J H, NS J, eds.). London: Edward Arnold; 2008.2445-70
9. Adham M, Kurniawan AN, Muhtadi AI, et al. Nasopharyngeal carcinoma in indonesia: Epidemiology, incidence, signs, and symptoms at presentation. *Chin J Cancer*. 2012;31(4):185-96.
10. Asri A. Penelitian Korelasi antara Latent Membrane Protein-1 Virus Epstein-Barr dengan P53 pada Karsinoma Nasofaring ( Penelitian Lanjutan ). 2012;1(1):4-6.
11. Salehiniya H, Mohammadian M, Mahdavifar N. Nasopharyngeal cancer in the world: epidemiology, mortality and risk factors. *World Cancer Research Journal*. 2018;5(1):1-8.
12. Faiza S, Rahman S, Asri A. Karakteristik Klinis dan Patologis Karsinoma Nasofaring di Bagian THT-KL RSUP Dr.M.Djamil Padang. 2013;5(1):90-6.
13. Wang Y, Lu X. The Incidence and Prognosis of Nasopharyngeal Carcinoma Patients With Family History. *Int J Radiat Oncol*. 2017;99(2):E381.
14. Zhang J, Qin T, Hong S, Liang W. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. 2015;(March).
15. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Publ Gr*. 2012;12(4):252-64.
16. Lee VHF, Lo AWI, Leung C, et al. Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma. 2016;(June).
17. Zheng L, Cao C, Cheng G, Hu Q, Chen X. Cytomembranic PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma. *Onco Targets Ther*.

- 2017;10:5483-7.
18. Li Y Fei, Ding J Wu, Liao L Min, Zhang Zhilin, Liao SS. Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. 2017;378-82.
  19. Zhou Y, Miao J, Wu H, Tang H, Kuang J. PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: The correlation with anemia and outcomes PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma : the correlation with anemia and outcomes. 2017;(April).
  20. Hsu M, Hsiao J, Chang K, Wu Y, Su I. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. *Mod Pathol*. 2010;23(10):1393-403.
  21. Wei W, Chuan D. *Nasopharyngeal Carcinoma*. In : *Johnson J.Rosen C Eds. Bailey's Head & Neck Surgery Otolaryngology*. 5th ed. Philadelphia: Lipincott Williams and Wilkins Publishers; 2014.1875-97
  22. Ondrey F, Wright S. *Neoplasm of Nasopharynx*. In: *Snow JB, Ballenger JJ, Editor Ballenger's Otorhinolaryngology Head and Neck Surgery*. 16th ed. Ontario: BC Decker Inc; 2003.1392-1407
  23. Brennan B. Nasopharyngeal carcinoma. *Orphanet J Rare Dis*. 2006;1(1):1-5.
  24. Liu Y, Du C, Lin C, Chan C, Chen C, Wang J. Increase morbidity from nasopharyngeal carcinoma and chronic pharyngitis or sinusitis among workers a. 2002:18-22.
  25. Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013. *JAMA Oncol*. 2015;1(4):505-527.
  26. L T, T L. *Benign and Maligna Tumours of Nasopharyng*. In *Cummings Otolaryngology Head and Neck Surgery*. 5th ed. (PW F, BH H, VJ L, JK N, MA R, KT R, eds.). Philadelphia: Elsevier; 2010.1348-57
  27. Rahman S, Andalas U. Clinical Presentation of Nasopharyngeal Carcinoma in West Sumatra , Indonesia. 2016;(June 2013):3-4.
  28. Klein G, Kashuba E. Nasopharyngeal Carcinoma. *Brenner's Encycl Genet Second Ed*. 2013;5:4-5.
  29. Guo X, Johnson RC, Deng H, Liao J. Evaluation of non-viral risk factor nasopharyngeal carcinoma in a high-risk population of Southern China. 2009;124(12):1-19.
  30. Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and Inequality in the Incidence and Mortality of Nasopharynx Cancer in Asia. *Osong Public Heal Res Perspect*. 2016;7(6):360-72.
  31. Xie SH, Tak I, Ah L, et al. Occupational risk factors for nasopharyngeal carcinoma in Hong Kong Chinese : a case-referent study. *Int Arch Occup Environ Health*. 2017;0(0):0.
  32. Safavi-naini A, Raad N, Ghorbani J, Chaibakhsh S, Ramezani- R. Incidence Trends and Geographical Distribution of Nasopharyngeal Carcinoma in Iran. 2009:24-8.
  33. Zeng M, Zeng Y. Pathogenesis and Etiology of Nasopharyngeal Carcinoma. In: Brady L, Heilmann H, Molls M, Nieder B, editors. *Nasopharyngeal CAnCER Multidisciplinary Management*. New York: Springer New York LLC; 2010. p. 9–26.
  34. Tabuchi K, Nakayama M, Nishimura B, Hayashi K, Hara A. Early Detection

- of Nasopharyngeal Carcinoma. *International Journal of Otolaryngology* 2011;1-6.
35. Tang F, Tang X, Tian D, Cao Y. Chemical carcinogenesis and nasopharyngeal carcinoma. In: Chen SS, editor. *Carcinogenesis, Diagnosis, and Molecular Targeted Treatment for Nasopharyngeal Carcinoma*. Rijeka: InTech; 2012. 61-82
  36. Chang ET, Adami H. The Enigmatic Epidemiology of Nasopharyngeal Carcinoma. 2006;15(10):1765-78.
  37. Armstrong RW, Imrey PB, Lye MS, Armstrong MJ, Yu MC, Sani S. Nasopharyngeal carcinoma in Malaysian Chinese: Occupational exposures to particles, formaldehyde and heat. *Int J Epidemiol*. 2000;29(6):991-98.
  38. Bosetti C, Mclaughlin JK, Tarone RE, Pira E, Vecchia C La. Formaldehyde and cancer risk : a quantitative review of cohort studies through 2006. 2008:29-43.
  39. Freeman LEB, Blair AA, Lubin JH, et al. Mortality From Solid Tumors Among Workers in Formaldehyde Industries : An Update of the NCI Cohort. 2013;1026(6):1015-26.
  40. Ekburanawat W, Ekpanyaskul C, Brennan P, et al. Evaluation of non-viral risk factors for nasopharyngeal carcinoma in Thailand: Results from a case-control study. *Asian Pacific J Cancer Prev*. 2010;11(4):929-32.
  41. Hutajulu SH, Kurnianda J, Tan IB. Therapeutic implications of Epstein – Barr virus infection for the treatment of nasopharyngeal carcinoma. 2014:721-36.
  42. Guo X, Johnson RC, Deng H, Liao J, Guan L, George W. Evaluation of non-viral risk factors for nasopharyngeal carcinoma in highrisk population of southern china. *HHS Public Access*. 2015;124(12):2942-7.
  43. Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. *Lancet*. 2015;6736(15):1-13.
  44. Mak HW, Lee SH, Chee J, Tham I, Goh BC. Clinical Outcome among Nasopharyngeal Cancer Patients in a Multi-Ethnic Society in. 2015:1-13.
  45. Wei WI, Kwong DLW. Current Management Strategy of Nasopharyngeal Carcinoma. 2010;3(1):1-12.
  46. Lee A, Lydiatt W, Colevas D, Glastonbury C, Le QT SB. *Nasopharyng. In: AJCC Cancer Staging Manual*. 8th ed. Chicago: Springer; 2017. 104-15.
  47. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez T, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. *J Immunother*. 2010;33(9):983-90.
  48. Liu G, Sido JM, Shen E. PD-1/PD-L1 Blockade in the Treatment of Nasopharyngeal Carcinoma. *J Nasopharyngeal Carcinoma*. 2017;4(2):10-13.
  49. Larbcharoensub N, Mahaprom K. Characterization of PD-L1 and PD-1 Expression and CD8+. 2018:1-7.
  50. Tulalamba W, Janvilisri T. Nasopharyngeal Carcinoma Signaling Pathway: An Update on Molecular Biomarkers. *Int J Cell Biol*. 2012:1-10.
  51. Dogan S, Hedberg ML, Ferris RL, Rath TJ, Assaad AM, Chiosea SI. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. *Head Neck*. 2014;36(4):511-6.
  52. Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting : Integrating Suppression and Promotion. *Science* 2011(331) :1565-70.



53. Economopoulou P, Kotsantis I, Psyrris A. Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. *Curr Treat Options Oncol*. 2016;17(8).
54. Weiping Z, Jedd D. W, Lieping C. PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations. *Sci Transl Med*. 2016;8(328).
55. Finn OJ. Immuno-oncology : understanding the function and dysfunction of the immune system in cancer. 2012;23(Supplement 8):8-11.
56. Wojtowicz ME, Dunn BK, Umar A. Immunologic Approaches to Cancer Prevention – Current Status, Challenges Author ' s Accepted Manuscript. *Semin Oncol*. 2015
57. Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. *Lancet Oncol*. 2017;18(12):e731-e741.
58. Boussiotis VA. The PD1 : PD-L1 / 2 Pathway from Discovery to Clinical implementation. 2016;7(12).
59. Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. *Ann N Y Acad Sci*. 2011;1217(1):45-59.
60. Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. *Oral Oncol*. 2014;50(7):627-32.
61. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. *Cancer Med*. 2013;2(5):662-73.
62. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. 2004;101(45):16004-9.
63. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. *Immunol Rev*. 2010;236(1):219-42.
64. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. *Proc Natl Acad Sci*. 2002;99(19):12293-7.
65. Munn DH, Munn DH. The host protecting the tumor from the host — targeting PD L1 expressed by host cells Find the latest version : The host protecting the tumor from the host — targeting PD - L1 expressed by host cells. 2018;128(2):570-2.
66. Schietinger A et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. *Immunity*. 2016;45:389-401.
67. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. *Cell Res*. 2017;27:109-18.
68. Zhu Q, Cai MY, Chen CL, et al. Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. *Oncimmunology*. 2017;6(5):1-10.
69. Fang W, Zhang J, Hong S, et al. EBV-driven LMP1 and IFN- $\gamma$ ; up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. *Oncotarget*. 2014;5(23):12189-202.
70. Zhao L, Liao X, Hong G, et al. Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma. 2019:1631-40.
71. Zhou Y, Shi D, Miao J, et al. PD-L1 predicts poor prognosis for

- nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load. *Sci Rep*. 2017;7(1):1-11.
72. Tsao SW, Tsang CM, Lo KW. Epstein – Barr virus infection and nasopharyngeal carcinoma. 2017.1-15
  73. Wu Y, Chen W, Xu ZP, Gu W. PD-L1 Distribution and Perspective for Cancer Immunotherapy — Blockade , Knockdown , or Inhibition. 2019;10(8):1-15.
  74. Jain A, Chia WK, Toh HC. Immunotherapy for nasopharyngeal cancer—a review. *Chinese Clin Oncol*. 2016;5(2):22-6.
  75. Dahlan S. Menggunakan Rumus Besar Sampel Secara Benar Dalam Besar Sampel Dan Cara Pengambilan Sampel. 2nd ed. Jakarta: Salemba Medika; 2009; 33-78
  76. Minichsdorfer C, Oberndorfer F, Krall C, Kornek G, Müllauer L, Wagner C and Fuehrer T . PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients. *Front. Oncol*. 2019; 9:1334; 1-10
  77. Bray F, Haugen M, Moger TA, Tretli S, Aalen OO, Grotmol T. Age-incidence curves of nasopharyngeal carcinoma worldwide: Bimodality in low-risk populations and aetiologic implications. *Cancer Epidemiol Biomarkers Prev*. 2008;17(9):2356–65
  78. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. *Cancer Cell*. 2001; vol 5:423–28.
  79. Yeung DCM, Yeung Z, Wong EWY, Vlantis AC, Chan JYK. Neck lymph node status on survival of regionally recurrent or persistent nasopharyngeal carcinoma. *Sci Rep*. 2020;10(1):1-8.
  80. Ruan Y, Hu W, Li W, Lu H, Gu H, Zhang Y, et al. Analysis of plasma EBV-DNA and soluble checkpoint proteins in nasopharyngeal carcinoma patients after definitive intensity-modulated radiotherapy. 2019;2019:1-10
  81. Wu L, Li C, Pan L. Nasopharyngeal carcinoma: A review of current updates. *Exp Ther Med*. 2018;15(4):3687-92.
  82. Melani W, Sofyan F. Karakteristik penderita kanker nasofaring di Rumah Sakit H . Adam Malik Medan Tahun 2011. *E-Jurnal FK-USU*. 2013;1(1):1-5
  83. Dawolo AP, Utama DS, Kasim BI. Profil Klinis Karsinoma Nasofaring di Departemen THTKL RSUP Dr. Mohammad Hoesin Palembang Tahun 2014-2015. *Maj Kedokt Sriwij*. 2019;49(1):1–9.
  84. Deng R, Lu J, Liu X, Peng XH, Wang J, Li XP. Pd-11 expression is highly associated with tumor-associated macrophage infiltration in nasopharyngeal carcinoma. *Cancer Manag Res*. 2020;12:11585-11596.
  85. Fedchenko N, Reifernath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review. 2014:1-12.
  86. Liu X, Shan C, Song Y, Du J. Prognostic value of programmed cell death ligand-1 expression in nasopharyngeal carcinoma: A meta-analysis of 1,315 patients. *Front Oncol*. 2019;9.
  87. Zhang Y, Zheng H, Zhan Y, et al. PD-L1 associated with the expression of cancer cell-intrinsic PD-1 and p-S6 proteins and predicted a good prognosis in nasopharyngeal carcinoma. 2020:1-13
  88. Cao Y, Chan KI, Xiao G, et al. Expression and clinical significance of PD-L1

- and BRAF expression in nasopharyngeal carcinoma. *BMC Cancer*. 2019;19(1):1-8.
89. Ju X, Zhang H, Zhou Z, Wang Q. Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy. *Am J Cancer Res*. 2020;10(1):1-11
  90. Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. *Oncogene*. 2018;37(34):4639-4661
  91. Casey SC, Baylot V and Felsher DW. MYC: master regulator of immune privilege. *Trends Immunol* 2017; 38: 298-305.
  92. Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, Beavis PA, Darcy PK, Martin BP, Spencer A, Traunbauer AK, Sadovnik I, Bauer K, Valent P, Bradner JE, Zuber J, Shortt J and Johnstone RW. BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. *Cell Rep* 2017; 18: 2162-74.
  93. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V and Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. *J Exp Med* 2014; 211: 781-90.
  94. Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN and Hung MC. Deubiquitination and stabilization of PD-L1 by CSN5. *Cancer Cell* 2016; 30
  95. Buttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, et al. Programmed death-ligand 1 immunohistochemistry testing: A review of analytical assays and clinical implementation in non-small-cell lung cancer. *J Clin Oncol*. 2017;35(34):3867-76.
  96. Handoko H, Gondhowiardjo S., Adham M. PD-L1 profile of nasopharyngeal cancer patients in Indonesia. *Ann Oncol*. 2019;30(November):112.
  97. Gondhowiardjo SA, Handoko, Adham M, et al. Tumor microenvironment predicts local tumor extensiveness in pd-11 positive nasopharyngeal cancer. *PLoS One*. 2020;15(3):1-10.